Who are Sodium Valproate treatment's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Duvyzat, Farydak, BELINOSTAT, Beleodaq, Istodax, Zolinza.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sodium-valproate-treatment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Sodium Valproate treatment — Competitive Intelligence Brief

Sodium Valproate treatment (Sodium Valproate treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Histone deacetylase inhibitor; anticonvulsant. Area: Neurology; Oncology.

marketed Histone deacetylase inhibitor; anticonvulsant Histone deacetylase (HDAC); GABA metabolism Neurology; Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Sodium Valproate treatment (Sodium Valproate treatment) — University of Pittsburgh. Sodium valproate inhibits histone deacetylase (HDAC) and enhances gamma-aminobutyric acid (GABA) neurotransmission in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sodium Valproate treatment TARGET	Sodium Valproate treatment	University of Pittsburgh	marketed	Histone deacetylase inhibitor; anticonvulsant	Histone deacetylase (HDAC); GABA metabolism
Duvyzat	GIVINOSTAT	Italfarmaco Spa	marketed	Histone Deacetylase Inhibitor [EPC]		2024-01-01
Farydak	PANOBINOSTAT	Secura	marketed	Histone Deacetylase Inhibitor	Histone deacetylase 4	2015-01-01
BELINOSTAT	BELINOSTAT		marketed	Histone Deacetylase Inhibitor [EPC]		2014-01-01
Beleodaq	belinostat	Acrotech Biopharma	marketed	Histone Deacetylase Inhibitor [EPC]	Histone deacetylase 1	2014-01-01
Istodax	ROMIDEPSIN	Teva Pharms Usa Inc	marketed	Histone Deacetylase Inhibitor	HDACs	2009-01-01
Zolinza	VORINOSTAT	Merck & Co.	marketed	Histone Deacetylase Inhibitor [EPC]	Histone deacetylase 6	2006-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Histone deacetylase inhibitor; anticonvulsant class)

University of Pittsburgh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sodium Valproate treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/sodium-valproate-treatment. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab